Double-Barreled CAR-T cells take aim at Hard-to-Treat myeloma

NCT ID NCT07003568

Recruiting now Disease control Sponsor: Beijing GoBroad Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new type of immune cell therapy that targets two proteins (BCMA and GPRC5D) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to treatment and has spread to other parts of the body. The main goal is to check safety in 18 participants, with some early looks at how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dual-targeting BCMA-GPRC5D CAR-T cells (a type of immune cell therapy)
What this could lead to: If it works, this could offer a new treatment option for patients with multiple myeloma that has spread outside the bone marrow and stopped responding to other therapies.
What could go wrong: This is a very early (Phase 1) and small trial (18 people) focused mainly on safety, not effectiveness. The therapy may cause serious side effects or not work well enough.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence refractory plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Contacts and locations

Locations

Shanghai Liquan Hospital
RECRUITING

Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.